The Battle against Biofilms: A Focus on Novel Antimicrobial Strategies and Their Mechanisms of Action
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiofilm Strategies".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 8363
Special Issue Editors
Interests: biofilms; antimicrobial resistance and tolerance; foodborne bacterial pathogens; virulence and pathogenesis; disinfection; novel (green) antimicrobials; food hygiene and safety; quorum sensing; intercellular interactions; bacterial stress adaptation
Special Issues, Collections and Topics in MDPI journals
Interests: biofilms; bioadhesion; microbial ecology; environmental microbiology; food microbiology; food hygiene and safety; foodborne pathogens; microscopy; omics
Special Issue Information
Dear Colleagues,
Biofilms are the default microbial growth mode in most environments, including both natural and human-made ones. These protect the enclosed cells from environmental perturbations, including physicochemical stresses and biocide exposure. In addition to their beneficial roles, mainly with respect to their crucial involvement in environmental sustainability issues (e.g., bioremediation, wastewater treatment, bioreactors producing beneficial compounds), biofilms are mostly known for the important problems these provoke in many areas, including persistent human infections, biofouling of medical devices (e.g., catheters, prosthetic heart valves), food contamination, surface corrosion, crop losses, problems in marine traffic, productivity losses, and considerable increases in energy consumption. The increased recalcitrance of biofilms to current antimicrobials has led to the search for novel, cost-efficient, and preferable eco-friendly antimicrobial strategies to combat them. These should be able to destroy the biofilm cells with the lowest possibilities for subsequent resistance development. This Special Issue seeks manuscripts dealing with novel antibiofilm strategies, especially those trying to unravel their modes of action at the sessile community and cellular levels. Both original research and review articles are welcome.
Dr. Efstathios Giaouris
Dr. Olivier Habimana
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel antibiofilm strategies
- antimicrobial resistance and tolerance
- natural and nature-inspired antimicrobials
- quorum sensing inhibitors
- next generation antimicrobials
- biofilm inhibition and eradication
- antibiofilm phytochemicals and plant extracts
- antibiofilm nanoparticles
- nanocoatings and surface modifications
- antibiofilm bioprotective cultures (e.g., lactic acid bacteria, bacilli)
- antibiofilm enzymes and bacteriophages
- antibiofilm photodynamic treatment
- antifouling agents and coatings
- synergistic antibiofilm approaches
- mechanisms of antibiofilm action
- clinical antibiofilm trials
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Control of clinical biofilms using bacteriophages: bench to bedside
Authors: Anusha R.,; Juliet Mohanraj,; Akshatha K,; Iddya Karunasagar,; Indrani Karunasagar,; Sambuddha Chakraborty;Ashwini Chauhan
Affiliation: Sambuddha Chakraborty and Ashwini Chauhan Department of Microbiology, Tripura University,
Biswajit Maiti, Nitte University Centre for Science Education and Research, Mangalore- 575018
DST Technology enabling center, Nitte University, Mangalore -575018
Title: Antibiofilm activity of brazilin-rich Caesalpinia sappan L. extract against Candida glabrata
Authors: V. Singaravel (first and corresponding author; [email protected]) R. Anitha (second author; [email protected]) J. Vinoth (third author; [email protected])
Affiliation: 1 Department of Medical Biochemistry, Dr. ALM Post-Graduation Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai 600 113, Tamil Nadu, India
2 Department of Biochemistry, St. Joseph’s College of Arts and Science (Autonomous), Cuddalore 607 001, Tamil Nadu, India
3 Haridraa Industries, S.F. No. 185 Idigarai Road, Teachers Colony, Coimbatore – 641 022, Tamil Nadu, India
Abstract: Most of the microbes form biofilms that adhere to biotic or abiotic surfaces. These biofilms reduce the efficacy of available antimicrobial agents. In this study, brazilin rich extract (BRE) studied for anticandidal and antibiofilm activities against fluconazole resistant clinical isolates of Candida glabrata. Biofilm formation assays, biofilm eradication assays, antimicrobial assays, crystal violet assay and XTT assay were utilized to investigate how BRE affect biofilm development. The BRE revealed strong anticandidal activity against C. glabrata with an MIC of 64 µg/mL. The sub-MIC doses (16, 32 and 64 µg/mL) BRE showed significant antibiofilm activity against fluconazole resistant clinical isolates of C. glabrata, with maximum biofilm reduction obtained at 32 µg/mL. These results show that BRE inhibits biofilm development and suggest that it might be useful for controlling non-candidal albicans candida infections and their biofilms.